Another study to keep an eye on is the Merck CETP inhibitor anacetrapib REVEAL study. During yesterday's Merck earnings call, it was stated "The REVEAL study, testing whether anacetrapib reduces cardiovascular events in at-risk patients already optimally treated with statin therapy, should provide data sometime after midyear." CETP inhibitors raise HDL, and all other CETP inhibitors have failed to show a reduction in cardiovascular events above standard of care statin treatment alone. So there's not a lot of confidence that anacetrapib will perform any differently. But the jury is still out. 

BearDownAZ